Rdar stock forecast with biotech valuations rebounding in

With biotech valuations rebounding in mid-2024, the RDAR stock forecast is benefiting from tailwinds in FDA approvals. Traders are eyeing a potential 15% upside if macro market conditions remain stable. Sep 4, 2025 · Raadr Inc. analyst estimates, including RDAR earnings per share estimates and analyst recommendations. Raadr Inc. (OTC PINK: RDAR), operating as Telvantis , has secured a new $45 million working capital facility through its Irish subsidiary in partnership with a leading European credit fund. The facility replaces a previous unsecured loan and features a five-year amortization term with reduced financing costs. The new arrangement aims to lower fixed-interest expenses while providing enhanced access to funding for growth initiatives in the telecommunications sector. This suggests the stock may continue tracking sector trends closely.